Peter Voorhees, MD

Dr Voorhees on the Clinical Implications of Cilta-Cel in Relapsed/Refractory Myeloma

July 9th 2025

Peter Voorhees, MD, details the clinical implications of cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma.

Exciting Future Horizons for CAR T in MM and Take-Home Messages

April 28th 2025

Experts share their closing thoughts and key take-home messages from the discussion, summarizing important insights and takeaways for enhancing patient care and treatment strategies.

Clinical Perspectives: Importance of Vaccinations and Infection Prevention Post CAR T, and Monitoring Strategies for Other Potential Late CAR T–Related Toxicities in R/R MM

April 28th 2025

Experts discuss strategies for managing and mitigating early vs late chimeric antigen receptor (CAR) T-cell therapy–related toxicities, offering advice to practitioners, and share additional clinical pearls on improving the overall CAR T process in academic and community settings.

Collaborative Approach in Managing Post CAR T Care Between Academic and Community Physicians in R/R MM

April 21st 2025

Experts discuss how they manage chimeric antigen receptor (CAR) T-cell therapy follow-up care, highlighting the coordination between academic and community settings to ensure comprehensive monitoring and support for patients.

Overcoming Barriers to CAR T Referral in R/R MM

April 21st 2025

Experts discuss the challenges and barriers to early referral for chimeric antigen receptor (CAR) T-cell therapy, including logistical, financial, and patient-related factors that may impact timely access to treatment.

Explaining CAR T: Key Points for Patient Counseling

April 14th 2025

Experts discuss what they share with patients when counseling or introducing chimeric antigen receptor (CAR) T-cell therapy, focusing on the treatment process, potential benefits, risks, and expectations.

Bridging to CAR T in R/R MM: Best Practices

April 14th 2025

Experts discuss their optimal strategy for bridging therapy when preparing patients to receive chimeric antigen receptor (CAR) T-cell therapy. They focus on selecting therapies that maintain disease control while awaiting CAR T infusion.

Strategic Timing for CAR T in R/R MM: The Importance of Early Referral

April 7th 2025

Experts discuss when physicians should consider referring patients to chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory multiple myeloma (R/R MM). They emphasize the importance of early referral and access to CAR T in earlier lines of therapy while commenting on the similarities and differences in referral timing, particularly for patients treated in the community.

Cilta-cel vs. Ide-cel: Key Data Updates and Clinical Decision-Making in R/R MM

April 7th 2025

Experts discuss how they decide between utilizing cilta-cel vs ide-cel in multiple myeloma, considering factors like disease characteristics, patient factors, and product differences, while reviewing the final progression-free survival (PFS) analysis from the KarMMA-3 study with ide-cel and key takeaways from the ASH 2024 update on minimal residual disease (MRD) negativity rates from CARTITUDE-4 with cilta-cel and its impact on clinical practice.

Sequencing CAR T in More Heavily Pretreated R/R MM as well in patients who deferred initial autologous HSCT

March 31st 2025

Experts discuss their clinical approach to using chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM), focusing on how they sequence CAR T with other treatment options like autologous hematopoietic stem cell transplantation (HSCT) and bispecific antibodies.

Optimizing CAR T in R/R MM: Treatment Paradigms and Patient Selection

March 31st 2025

Experts discuss where chimeric antigen receptor (CAR) T-cell therapy currently fits in the treatment paradigm, highlighting the patient factors and disease characteristics that influence its use in clinical decision-making.

Dr. Voorhees on the Utilization of Proteasome Inhibitors for Newly Diagnosed Multiple Myeloma

November 2nd 2022

Peter Voorhees, MD, discusses developments in the efficacy and application of proteasome inhibitors for patients with newly diagnosed multiple myeloma.

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th 2021

Dr. Voorhees on Updated Results of the GRIFFIN Trial in Multiple Myeloma

December 7th 2020

Peter Voorhees, MD, a multiple myeloma specialist at Levine Cancer Institute, of Atrium Health, discusses updated results of the GRIFFIN trial in multiple myeloma.

Future of BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020

Bispecific Antibodies for Multiple Myeloma

July 17th 2020

Differentiating among CAR T Products for Multiple Myeloma

July 17th 2020

Development of CAR T Cells in Multiple Myeloma

July 17th 2020

Using Antibody-Drug Conjugates in Multiple Myeloma

July 17th 2020

BCMA-Targeted Therapies in Multiple Myeloma

July 17th 2020